A trial can collect excellent data and still leave an important question unanswered. It might measure an endpoint that matters little to patients, enroll people unlike those expected to use the treatment, or be too small to distinguish a useful effect from noise.
AI can help teams explore these choices before enrollment. It can organize prior evidence, compare patient characteristics, and support models that simulate possible outcomes. Its contribution depends on whether the question, assumptions, and comparison are clear.
A convincing simulation is an argument about what could happen under specified conditions. It is not evidence that a treatment works.
Why Trials Fail
The simplest reason is that the treatment does not provide the hoped-for benefit, or its harms outweigh that benefit. Better design cannot manufacture an effect that is absent.
Design can still make a real difference. A poorly chosen measurement may miss the relevant change. An overly restrictive eligibility rule may make recruitment impractical. A short observation period may overlook a delayed outcome. Missing follow-up can leave the analysis dependent on assumptions that are hard to defend.
Start by stating the intended treatment comparison in ordinary language: in which patients, compared with what, measured how, and over what period?
People with the specified condition and persistent symptoms despite usual care.
The add-on treatment versus placebo, both alongside the same usual care.
A prespecified symptom measurement, with its relevance to patients established.
At a specified time, with a plan for discontinuation, rescue treatment, and missing data.
AI-Designed Clinical Protocols
A model can help compare eligibility criteria against available patient records or summarize how earlier studies measured an outcome. Pharmacokinetic and pharmacodynamic models can explore relationships between exposure and response. Simulation can examine how a proposed analysis behaves under different plausible scenarios.
These tasks need different evidence. A model of recruitment does not establish treatment benefit. A molecular response marker does not automatically establish a benefit patients can feel or experience. A dose simulation needs suitable data and a clear account of uncertainty.
At AgentCures, connecting analyses with protocol drafts is part of our approach. The useful output is a proposal with inspectable assumptions, ready for clinical and statistical review.
A More Patient-Centered Trial
Patients can help establish which outcomes are meaningful and which study visits are burdensome. A difference that is statistically detectable may still be too small to matter in daily life.
Consider a fictional symptom scale. A team might simulate true average treatment differences of five, ten, and fifteen points. These are alternative assumptions, not three predictions the model knows to be correct.
100 per group, 200 participants total.
Teaching model: independent normal outcomes; known standard deviation of 20 points in both groups; equal allocation; one final two-sided z-test at 5%; complete follow-up. Values use a normal-distribution calculation, not patient data or a fitted AI model. Real trial planning requires additional assumptions and expert review.
The explorer illustrates one narrow relationship: larger samples make a fixed true difference easier to detect under the model. It does not determine what difference is clinically meaningful, whether recruitment is feasible, or which treatment participants should receive.
It also shows why an optimistic effect assumption is consequential. Designing around a large benefit can leave a study poorly equipped to detect a smaller benefit that still matters.
Faster Design Reviews
A useful simulation plan includes an ineffective treatment as well as favorable scenarios. It should also examine weaker effects, different variability, missing observations, and any planned interim decisions.
For adaptive designs, the team specifies how accumulating information can change the study. Possible adaptations include stopping early under defined conditions or adjusting aspects of enrollment. The rules and their statistical consequences need evaluation before they are used.
FDA’s adaptive design guidance discusses design, conduct, reporting, and the role of simulation. “Adaptive” does not mean changing the plan whenever an early result looks attractive. Repeated opportunities to declare success can affect false-positive rates unless the design accounts for them.
AI can help prepare and compare scenarios. The statistical model and decision rules need to remain explicit, with calculations that specialists can reproduce independently.
Regulatory-Ready Documentation
The protocol should explain the treatment effect it aims to estimate, including how events such as treatment discontinuation or rescue medication will be handled in defining that question. These choices can change the meaning of the result.
The ICH E9(R1) framework connects the trial objective to that precisely defined treatment effect, known as an estimand, and to sensitivity analyses. It helps expose ambiguity before a study begins.
Keep simulation code, input assumptions, output summaries, and protocol versions connected. If an assumption changes, reviewers should see which design recommendation depended on it. A generated paragraph saying the study is “adequately powered” is insufficient without the calculation and its basis.
The Impact
The best use of AI in trial design is to make alternatives easier to investigate and harder to confuse. A team can examine whether a proposal still works when its assumptions become less favorable, rather than presenting only the most encouraging scenario.
The final design needs a meaningful clinical question, a credible comparison, and an analysis aligned with that question. Simulation supports those decisions when it helps people understand what the trial can, and cannot, answer.